Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Microcap & Penny Stocks : Pharmos(PARS) -- Ignore unavailable to you. Want to Upgrade?

To: David Israel-Rosen who wrote (570)	4/8/1998 7:40:00 AM
From: David Israel-Rosen	Respond to of 1491

The highlight of the report: Strong buy !!! 18 months target price $6.25 28 cents net in 2000 ($12,000,000 after tax) this only based on existing products !!! contribution of pipe line to valuation model ZERO !!!! Fully diluted # of shares - 42,000,000 Best of luck, WE WILL GET A MENTION OF THE REPORT SOON ON THE NET !!!

To: David Israel-Rosen who wrote (570)	4/8/1998 7:58:00 AM
From: David Israel-Rosen	Read Replies (2) \| Respond to of 1491

Post from Yahoo A very informative and insightful report on Pharmos in the April issue of Neuroinvestment newsletter. Pharmos is the feature company. The scope of Pharmos' neurodrug HU-211 is fully explained as to its current state of development and the areas of which it is being tested (stroke, TBI, multiple sclerosis, intestinal bowel disorders, glaucoma). A very positive outlook. Also, it discusses Pharmos' cancer drug analogs (over 100) for Tamoxifen. The most recent news headlines has brought this breast cancer drug to the forefront of discussion. Preclinical studies indicate that Pharmos' analog, Tamoxifen Methiodide, reduces the side effects like osteoporosis, does not trigger uterine cancer, and may be more effective in slowing breast tumor progression. Other possible areas for it are melanoma and pancreatic cancer. Pharmos' drug delivery systems are also discussed and at this stage, Pharmos' is awaiting partners with therapeutic drugs which would benefit from their technology. The three eye drugs, Lotemax, Alrex, and LE-T were also reviewed very positively. The newsletter predicts $1.02 per share earnings in 2001. At 30x P/E, thats a $30+ stock price!!! It says that Pharmos' current price does not fully account for Lotemax/Alrex, and accords no value to HU-211 which is the "crown jewel" of Pharmos' portfolio. Based on its potential, and near term revenue from Lotemax/Alrex, their year end 1998 price target is $8 . E